Cancer- associated fibroblasts (CAFs) are actively involved in breast carcinoma. Our previous study demonstrated that the majority of these CAFs were smooth muscle actin (SMA) positive and were therefore termed peritumoral myofibroblast (PMY). Glucocorticoid, linked or not with its receptor (GR), has been postulated to serve a major role in normal breast and breast carcinoma; however, their role in CAFs remains poorly understood. The aim of the present study was to assess the presence of GR in breast CAFs and particularly in PMY in 56 cases of invasive breast carcinoma in correlation with clinicopathological parameters, by immunohistochemistry. GR was observed in CAFs in 51 cases (91%) and were more frequent in luminal A subtype (19/19 cases; 100%). The stromal expression was statistically correlated with the tumor grade (P=0.03), the Ki-67 index (P=0.003) and the presence of GR in the epithelial component (P=0.01). The demonstration of a frequent expression of GR in breast CAFs may serve as an interesting target for future therapeutics for the regulation of the tumoral breast microenvironment.
cancer associated fibroblastperitumoral myofibroblastglucocorticoidglucocorticoid receptorbreast carcinomastromaIntroduction
Glucocorticoids (GCs) are essential for survival and serve a major role in embryonic development, tissue homeostasis and in the regulation of the inflammatory response (1,2). In breast, the functions of GCs are complex and depend, in part, if they are linked to their receptor (GR) and consist of the control of milk secretion, differentiation and apoptosis (3). Morphologically, previous studies have demonstrated that GR nuclear expression is observed both in normal breast, in situ carcinoma and less frequently in invasive carcinoma (4–7). In invasive tumors, their expression is limited in tumors with a small size, low grade, good prognosis and expressing estrogen receptor (ER) (4,7). In addition, our previous study clearly demonstrated that dexamethasone has an antiproliferative effect in the MCF-7 breast cells that express GR (8).
Over previous years, the tumor-associated stroma and, in particular, the cancer associated fibroblasts (CAFs) have been demonstrated to serve a crucial role in cancer pathogenesis (9,10).
Our previous study clearly demonstrated that the majority of these CAFs were smooth muscle actin (SMA)-positive with a myofibroblastic-like phenotype and that the presence of these peritumoral myofibroblasts (PMY) is important both in situ and in invasive breast carcinoma of no special type (11). This is also important in metastatic disease by promoting tumor invasion, growth and angiogenesis through paracrine factors and/or direct cell-cell crosstalk (11–13).
Our previous study demonstrated the presence of ER or progesterone receptors (PR); however, the presence and potential role of GR is poorly understood in breast carcinoma PMYs (4).
Therefore, the present study aimed to assess, by immunohistochemistry, the presence or absence of GR in breast CAFs and in CAFs smooth muscle positive/PMY in correlation with clinicopathological variables. Investigating this may assist with elucidating the role of GR in breast carcinoma.
Materials and methodsPatient selection
Breast tissue samples were retrieved from the Departments of Pathology at the Erasme Hospital and IRIS South Hospital (Brussels, Belgium), and consisted of 56 cases of invasive carcinoma. The present study was approved by the Ethics Committee from Erasme University Hospital (no. P2014/418).
Immunohistochemistry
The immunohistochemical assessment of ER, PR, Ki-67 and human epidermal growth factor receptor (HER)2 was routinely performed using an antigen retrieval method using the Leica BOND-III fully automated system (Leica Microsystems, Ltd., Newcastle, UK), as previously described (4). According to these parameters, carcinoma were divided into five groups, as previously described (14): Luminal A (n=19), Luminal B (n=12), HER2+/ER+ (n=7), HER2+/ER- (n=9) and triple negative (n=9). In addition, the following parameters were also included for each patient: Age, stage, tumoral size and lymph node status. All parameters are shown in the Table I.
For the demonstration of GR, a manual technique was applied. Tissue sections (4 µm) were cut sequentially and mounted onto superfrost-treated slides (Menzel-Gläser, Braunschweig, Germany). The slides were dried overnight at 37°C prior to deparaffinization in xylene and rehydration through graded ethanols. For epitope retrieval, the slides were immersed in a waterbath at 95–99°C for 90 min with an ethylenediamine tetraacetic acid buffer (pH 9.0; S236; Dako Corp., Glostrup, Denmark). The slides were subsequently cooled in the buffer for 20 min at room temperature. H2O2 (0.3%) was subsequently added to the slides and incubated for 30 min. The tissues were then incubated for 1 h with a monoclonal antibody against the N-terminus of the GR (clone 4H2; cat. no. NCL-GCR; 1:25; Novocastra Laboratories, Newcastle, UK) (4).
Double immunostaining
In addition, for the specific visualization of the expression of ER/PR and GR in SMA-positive CAFs, a double stain was also performed by using the EnVision G/2 double stain system (Dako Corp.), as previously described (15). The same monoclonal antibodies (ER, PR and GR) described above were applied to rehydrated paraffin tissue sections and allowed to incubate for 1 h at room temperature. Endogenous peroxidase was inhibited and 3,3′-diaminobenzidine was used to visualize the binding of these primary antibodies. The sections were subsequently incubated for 1 h with a secondary antibody against SMA (clone αSM-1; 1:50; Novocastra Laboratories, Newcastle, UK). Alkaline phosphatase-conjugated secondary antibody and fuchsin as substrate chromogen system were used to complete the secondary immunostain. Negative controls used the replacement of the different primary antibodies with the corresponding isotypes. In addition, to ensure the absence of PMY in the normal breast, 10 cases of normal breast tissue from patients who underwent plastic surgery were also included.
Immunohistochemical evaluation
All the slides were examined by two independent observers (Xavier Catteau and Jean-Christophe Noël) and the evaluation of ER, PR and GR was made independently by the two pathologists using the Allred score (16), and estimated the proportion of positive CAFs (0, no positive cells; 1, ≤1; 2, 1–10; 3, 11–33; 4, 34–66; 5, 67–100% positive cells) and the average staining intensity (0, negative; 1, weak; 2, Intermediate; 3, strong). The proportion score and the intensity score were added to obtain a total score ranging from 0–8. Subsequently, three grades of immunoreactivity were established: Score 0–2, negative; score 3–4, weak positivity; score 5–8, strong positivity.
Statistical analysis
The correlation analysis was performed. χ2-test and Fisher's exact test were used. All statistical analyses were performed using XLSTAT software (Addinsoft, Paris, France). P<0.05 was considered to indicate a statistically significant difference.
Results
Weak or strong expression of GR in CAFs was observed in 10 cases (18%) and 41 cases (73%), respectively. A total of 5 cases were negative (5%; Table I). The stromal expression was frequent in luminal A tumor (100% of cases; Fig. 1A) and is statistically correlated with the tumor grade (P=0.03), the Ki-67 index (P=0.003) and GR status in glandular/carcinomatous component (P=0.01); however, was not correlated with age, tumor size, lymph node status and the expression of ER or PR, at least with a positive status for the latest as ≥1% in accordance with the World Health Organization recommendations (Table I). The double stain immunohistochemistry confirming unequivocally that among these CAFs, SMA-positive PMY clearly showed a nuclear staining of GR (Fig. 1B).
Discussion
For numerous years, the majority of studies in breast carcinoma have been focused predominantly on the epithelial component; however, recently CAFs and in particular CAFs SMA-positive PMY have been demonstrated to serve an important role in cancer pathogenesis as a result of paracrine cross-interaction between these and epithelial cancer cells. Indeed CAFs/PMY are able to secrete various factors implicated in invasion, matrix remodeling, cell proliferation, differentiation and apoptosis. In breast carcinoma, the hormonal regulation of epithelial cells is well documented and is the result of interaction between estrogen and progesterone, and their respective receptors, at least in hormone-dependent tumor types (16,17). The role of GCs in normal breast is more controversial and likely depends on the balance between targets of linked and non-linked GR with opposing functions: linked GR being involved in maintaining functional differentiation and non-linked GR appearing to be proapoptotic (3,6). In breast carcinoma, the GCs acting through their nuclear receptors are considered as a potential tumor suppressor promoting accurate chromosome segregation during mitosis occurring tumoral cell division (6,18,19). Indeed, according to these data, our previous study demonstrated an antiproliferative effect of dexamethosone in the MCF-7 breast cancer cells line that contains nuclear GR (8). The underlying mechanisms of hormonal regulation of CAFs/PMY remain to be determined; however, our previous study and other previous studies have clearly demonstrated that ER and PR were not present in these cells.
By contrast, the present study clearly demonstrated the presence of a marked GC nuclear immunoreactivity of CAFs in 73% of cases. In addition, this strong immunoreactivity was demonstrated by double labeling in CAFs SMA-positive PMY (Fig. 1) for the first time, to the best of our knowledge. This strong CAFs immunoreactivity was typically more frequent in luminal A (100%) compared with in other subtypes. In addition, it appeared to be correlated with different conventional clinicopathological parameters, including the grade (P=0.03) and Ki-67 index (P=0.003). The CR expression in CAFs was also more frequent when these receptors were present in the carcinomatous counterpart (P=0.01). These data suggested that, as previously shown for matrix metalloproteinase-2, the characteristics and properties of CAFs present in breast carcinoma microenvironment are probably complex and different from one subtype to another (10,20–22).
GCs are considered as agents capable of regulating the proliferation of myofibroblasts in different pathologies where they serve a major role as wound healing or asthma (23,24). Previously, in a myofibroblast cell line associated with colonic carcinoma, dexamethasone inhibited the expression of different classical procarcinogenic factors, including tenascin C, hepatocyte growth factor and transforming growth factor-β, in a receptor-dependent manner (25).
The present data are interesting since over the last few years it appears that in addition to the development concerning the classical therapies (hormone therapies, chemotherapies and immunotherapies), the peritumoral stroma served as potential target therapy in various carcinomas (9,24,25). Finally, even if it remains hypothetical, it has been postulated that the stress through GCs can be a promoting agent in breast cancer (26,27). From this point of view, demonstrating the presence of GR in the CAFs may be important.
The demonstration of a frequent expression of GR in breast CAFs may serve as an interesting target for future therapy in the regulation of the tumoral breast microenvironment. Naturally, future research is required, firstly to establish with larger cohorts the assocaition between the presence of GR in CAFs and the overall survival, and to understand how a therapy may influence the CAF associated with breast carcinoma. Such investigations are in progress.
Acknowledgements
The authors would like to thank Mrs. Isabelle Fayt and Mrs. Nadège De Kindt for their excellent technical work. The present study was supported by the Institut de Recherche Scientifique de Pathologie et de Génétique.
ReferencesHollenbergSMWeinbergerCOngESCerelliGOroALeboRThompsonEBRosenfeldMGEvansRMPrimary structure and expression of a functional human glucocorticoid receptor cDNA318635641198510.1038/318635a02867473ArangoLievanoMLambertWMJeanneteauFMolecular biology of glucocorticoid signaling8723357201510.1007/978-1-4939-2895-8_226215989RitterHDMuellerCRExpression microarray identifies the unliganded glucocorticoid receptor as a regulator of gene expression in mammary epithelial cells14275201410.1186/1471-2407-14-27524755251BuxantFEngohanAlogheCNoëlJCEstrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer18254257201010.1097/PAI.0b013e3181c1018019875955LienHCLuYSChengALChangWCJengYMKuoYHHuangCSChangKJYaoYTDifferential expression of glucocorticoid receptor in human breast tissues and related neoplasms209317327200610.1002/path.198216639692VilascoMCommunalLMourraNCourtinAForgezPGompelAGlucocorticoid receptor and breast cancer130110201110.1007/s10549-011-1689-621818591AbduljabbarRNegmOHLaiCFJerjeesDAAlKaabiMHamedMRTighePJBuluwelaLMukherjeeAGreenARAliSClinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer150335346201510.1007/s10549-015-3335-125762479BuxantFKindtNLaurentGNoëlJCSaussezSAntiproliferative effect of dexamethasone in the MCF-7 breast cancer cell line1240514054201526080744OtrantoMSarrazyVBontéFHinzBGabbianiGDesmoulièreAThe role of the myofibroblast in tumor stroma remodeling6203219201210.4161/cam.2037722568985GandelliniPAndrianiFMerlinoGD'AiutoFRozLCallariMComplexity in the tumour microenvironment: Cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types3596106201510.1016/j.semcancer.2015.08.00826320408CatteauXSimonPVanhaeverbeekMNoëlJCVariable stromal periductular expression of CD34 and smooth muscle actin (SMA) in intraductal carcinoma of the breast8e57773201310.1371/journal.pone.005777323469238CatteauXSimonPNoëlJCMyofibroblastic stromal reaction and lymph node status in invasive breast carcinoma: Possible role of the TGF-β1/TGF-βR1 pathway14499201410.1186/1471-2407-14-49925011545CatteauXSimonPNoëlJCMyofibroblastic reaction is a common event in metastatic disease of breast carcinoma: A descriptive study9196201410.1186/s13000-014-0196-625339428PreatFSimonPNoelJCDifferences in breast carcinoma immunohistochemical subtypes between immigrant Arab and European women926201410.1186/1746-1596-9-2624495621NoelJCFaytIBuxantFProliferating activity in paget disease of the nipple16710201010.1007/s12253-009-9179-420016962AllredDCHarveyJMBerardoMClarkGMPrognostic and predictive factors in breast cancer by immunohistochemical analysis1115516819989504686SenkusEKyriakidesSOhnoSPenaultLlorcaFPoortmansPRutgersEZackrissonSCardosoFESMO Guidelines Committee: Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up26Suppl 5v8v30201510.1093/annonc/mdv29826314782MitreAguilarIBCabreraQuinteroAJZentella-DehesaAGenomic and non-genomic effects of glucocorticoids: Implications for breast cancer8110201525755688MatthewsLCBerryAAMorganDJPoolmanTMBauerKKramerFSpillerDGRichardsonRVChapmanKEFarrowSNGlucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy11254795484201510.1073/pnas.141135611225847991Rønnov-JessenLBissellMJBreast cancer by proxy: Can the microenvironment be both the cause and consequence?15513200910.1016/j.molmed.2008.11.00119091631KaragiannisGSPoutahidisTErdmanSEKirschRRiddellRHDiamandisEPCancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue1014031418201210.1158/1541-7786.MCR-12-030723024188PowellDWMyofibroblasts: Paracrine cells important in health and disease111271292discussion 292-293200010881346HinzBPhanSHThannickalVJPrunottoMDesmoulièreAVargaJDe WeverOMareelMGabbianiGRecent developments in myofibroblast biology: Paradigms for connective tissue remodeling18013401355201210.1016/j.ajpath.2012.02.00422387320GroseRWernerSKesslerDTuckermannJHuggelKDurkaSReichardtHMWernerSA role for endogenous glucocorticoids in wound repair3575582200210.1093/embo-reports/kvf11912034758DrebertZBrackeMBeckIMGlucocorticoids and the non-steroidal selective glucocorticoid receptor modulator, compound A, differentially affect colon cancer-derived myofibroblasts14992105201510.1016/j.jsbmb.2015.02.00225666906MichaelYLCarlsonNEChlebowskiRTAickinMWeihsKLOckeneJKBowenDJRitenbaughCInfluence of stressors on breast cancer incidence in the Women's Health Initiative28137146200910.1037/a001298219290705AntonovaLAronsonKMuellerCRStress and breast cancer: From epidemiology to molecular biology13208201110.1186/bcr283621575279
Immunohistochemical staining of CAFs. (A) A typical example of glucocorticoid receptor in CAFs (arrows). Note the strong immunoreactivity score of these cells by comparison with the epithelial carcinomatous component, which is negative (magnification, ×10). (B) The double staining immunohistochemistry confirmed the positivity of these nuclear receptors (brown) in α-smooth muscle actin positive CAFs/peritumoral myofibroblats stained in red (arrow) (magnification, ×40). The immunoreactivity for glucocorticoid receptor is moderate. CAF, cancer associated fibroblast.
Association of clinicopathological characteristics with immunohistochemical levels of GR in the peritumoral stroma.
GT expression in the stroma
Characteristic
No. cases (%)
Strong
Weak
Negative
P-value
Age, years
0.56
≤50
24 (43)
18
5
1
>50
32 (57)
23
5
4
Tumor size, mm
1
<20
28 (50)
21
5
2
≥20
28 (50)
20
5
3
Stage
0.81
T1
28 (50)
21
5
2
T2
21 (37.5)
15
3
3
T3
7 (12.5)
5
2
0
Tumor grade
0.03
Grade 1
10 (17.9)
10
0
0
Grade 2
22 (39.2)
12
8
2
Grade 3
24 (42.9)
19
2
3
Lymph node status
0.19
Negative
29 (51.8)
24
4
1
Positive
27 (48.2)
17
6
4
ER status
0.64
Negative
18 (32.1)
14
2
2
Positive
38 (67.9)
27
8
3
PR status
0.39
Negative
23 (41.1)
15
6
2
Positive
33 (58.9)
26
4
3
Ki-67 index, %
0.003
≤14
19 (33.9)
19
0
0
>14
37 (66.1)
22
10
5
HER 2 status
0.2
Negative
40 (71.4)
31
7
2
Positive
16 (28.6)
10
3
3
Intrinsic subtype
0.189
Luminal A
19 (33.9)
19
0
0
Luminal B/HER2−
12 (21.4)
5
5
2
Luminal B/HER2+
7 (12.5)
4
2
1
HER2+
9 (16.1)
6
1
2
Triple negative
9 (16.1)
7
2
0
GR status in glands
0.01
Negative
26 (46.4)
15
6
5
Positive
30 (53.6)
26
4
0
P-values in bold are statistically significant (P<0.05). ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; GR, glucocorticoid receptor.